Atacicept, part of a new class of therapies targeting immune-mediated factors in rare kidney disease, inhibits cytokines BAFF and April to reduce autoantibody production. Phase 2 results indicate significant stabilization of disease markers, setting a high standard for competitors. Anticipation grows for Vera’s upcoming Phase 3 trial to further assess the drug’s efficacy in IgA […]